Skip to main content

3 Result(s)

within U. Krug Remove this filter Hematology Remove this filter Stem Cells Remove this filter

and

  1. No Access

    Article

    Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT

    Non-relapse mortality after Allo-SCT has significantly decreased over the last years. Nevertheless, relapse remains a major cause for post SCT mortality in patients with AML and high-risk myelodysplastic syndr...

    T Sauer, G Silling, C Groth, F Rosenow, U Krug, D Görlich… in Bone Marrow Transplantation (2015)

  2. No Access

    Article

    CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT

    After allo-SCT, analysis of CD34+ lineage-specific donor cell chimerism (DCC) is a sensitive method for monitoring minimal residual disease in patients with AML or myelodysplastic syndrome (MDS) with CD34 express...

    F Rosenow, A Berkemeier, U Krug, C Müller-Tidow, J Gerss… in Bone Marrow Transplantation (2013)

  3. No Access

    Article

    High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases

    Germ cell cancer (GCC) is curable in metastatic stages. The International Germ Cell Cancer Collaborative Group (IGCCCG) reports a poor prognosis subgroup with a 5-year survival of 48%. High-dose chemotherapy w...

    M Mohr, I Hartig, T Kessler, C Hamisch, S Kliesch, U Krug… in Bone Marrow Transplantation (2012)